We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Labcorp (LH) Q1 Earnings
Read MoreHide Full Article
In its upcoming report, Labcorp Holdings (LH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.09 per share, reflecting an increase of 6.5% compared to the same period last year. Revenues are forecasted to be $3.5 billion, representing a year-over-year increase of 4.7%.
Over the last 30 days, there has been an upward revision of 0.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Labcorp metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- Diagnostics Laboratories' should come in at $2.75 billion. The estimate indicates a year-over-year change of +4.6%.
Analysts forecast 'Revenues- Biopharma Laboratory Services' to reach $746.35 million. The estimate indicates a change of +3.5% from the prior-year quarter.
The consensus among analysts is that 'Adjusted Operating Income- Diagnostics Laboratories' will reach $453.19 million. The estimate compares to the year-ago value of $427.50 million.
Analysts expect 'Adjusted Operating Income- Biopharma Laboratory Services' to come in at $115.12 million. Compared to the present estimate, the company reported $106.90 million in the same quarter last year.
Shares of Labcorp have demonstrated returns of -2.7% over the past month compared to the Zacks S&P 500 composite's +12.2% change. With a Zacks Rank #2 (Buy), LH is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Labcorp (LH) Q1 Earnings
In its upcoming report, Labcorp Holdings (LH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.09 per share, reflecting an increase of 6.5% compared to the same period last year. Revenues are forecasted to be $3.5 billion, representing a year-over-year increase of 4.7%.
Over the last 30 days, there has been an upward revision of 0.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Labcorp metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- Diagnostics Laboratories' should come in at $2.75 billion. The estimate indicates a year-over-year change of +4.6%.
Analysts forecast 'Revenues- Biopharma Laboratory Services' to reach $746.35 million. The estimate indicates a change of +3.5% from the prior-year quarter.
The consensus among analysts is that 'Adjusted Operating Income- Diagnostics Laboratories' will reach $453.19 million. The estimate compares to the year-ago value of $427.50 million.
Analysts expect 'Adjusted Operating Income- Biopharma Laboratory Services' to come in at $115.12 million. Compared to the present estimate, the company reported $106.90 million in the same quarter last year.
View all Key Company Metrics for Labcorp here>>>Shares of Labcorp have demonstrated returns of -2.7% over the past month compared to the Zacks S&P 500 composite's +12.2% change. With a Zacks Rank #2 (Buy), LH is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .